Related Experiment Video

Updated: May 28, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Functional evaluation of genetic and environmental regulators of p450 mRNA levels

Dazhi Wang1, Zhengwen Jiang, Zhongyang Shen

  • 1Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Plos One
|October 15, 2011
PubMed

Insights

Inter-individual differences in drug metabolism are influenced by Cytochrome P450 (CYP) gene expression. This study identified specific genetic and environmental factors driving variations in major CYP genes, crucial for personalized medicine.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Drug Metabolism

Background:

  • Cytochrome P450 (CYP) enzymes are critical for drug clearance, and variations in their activity contribute to inter-individual differences in drug response, potentially leading to toxicity or inefficacy.
  • While genetic and environmental factors influencing CYP gene expression are known, their specific roles in modulating inter-individual expression variations remain incompletely understood.
  • Understanding these regulatory factors is essential for optimizing drug therapy and minimizing adverse events.

Purpose of the Study:

  • To investigate the determinants of mRNA expression variations for seven major Cytochrome P450 genes (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5) in a Chinese population.
  • To differentiate the contributions of cis-acting genetic factors (gene copy number, functional SNPs) and trans-acting factors (mRNA levels of regulators, non-synonymous SNPs) in modulating CYP gene expression.
  • To identify the roles of environmental factors and global/specific regulatory networks in CYP gene expression variability.

Main Methods:

  • Measurement of mRNA levels for seven major CYP genes and housekeeping genes in 96 liver biopsy samples from the Chinese population.
  • Analysis of trans-acting factors (regulator gene mRNA, non-synonymous SNPs) and cis-acting factors (gene copy number, functional SNPs) associated with CYP gene expression.
  • Application of partial correlation analysis and Unweighted Pair Group Method with Arithmetic Mean (UPGMA) clustering to dissect regulatory networks and identify key determinants of expression variation.

Main Results:

  • Positive correlations were observed between mRNA levels of most CYP genes, regulator genes, and housekeeping genes.
  • Partial correlation analysis revealed gene-specific regulatory networks, with cis-acting variants potentially influencing CYP2D6 and CYP3A5 expression.
  • Environmental inducers appeared significant for CYP1A1 and CYP1A2 variations, while global regulators were key for CYP2C9 expression.

Conclusions:

  • Expression variations of major Cytochrome P450 genes are influenced by a combination of cis-acting genetic variants, trans-acting factors, and environmental inducers in a gene-specific manner.
  • Cis-acting genetic variants are likely major drivers for CYP2D6 and CYP3A5 expression variability.
  • Environmental factors and global regulators play significant roles in the expression of specific CYP genes, highlighting the complexity of drug metabolism regulation.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the addition of a...